Atossa Therapeutics Q3 EPS $(0.05) Beats $(0.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics (NASDAQ:ATOS) reported a Q3 EPS loss of $(0.05), surpassing the consensus estimate of $(0.07) by 28.57%. This represents a 16.67% improvement from the $(0.06) per share loss reported in the same quarter last year.
November 13, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics reported a smaller-than-expected Q3 loss per share of $(0.05), beating estimates by 28.57% and showing year-over-year improvement.
Beating EPS estimates typically generates positive sentiment among investors, suggesting a potential short-term increase in stock price. The improvement over last year's loss may also indicate progress in the company's financial performance, which can be seen as a positive sign for future growth.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100